Arimura Eiichirou, Kotoh Kazuhiro, Nakamuta Makoto, Morizono Shusuke, Enjoji Munechika, Nawata Hajime
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-5282, Japan.
World J Gastroenterol. 2005 Sep 28;11(36):5601-6. doi: 10.3748/wjg.v11.i36.5601.
To clarify the importance of complete treatment by PEIT.
A total of 140 previously untreated cases of HCC were enrolled in this study from 1988 to 2002. The inclusion criteria were: a solitary tumor less than 4 cm in diameter or multiple tumors, fewer than four in number and less than 3 cm in diameter, without extrahepatic metastasis or vessel invasion. As general principles for the treatment of HCC, the patients underwent transcatheter arterial chemoembolization (TACE) prior to PEIT. After the initial treatment of the patients, ultrasonography and computed tomography were performed, and measurement of serum levels of alpha-fetoprotein (AFP) was determined. When tumor recurrences were detected, PEIT and/or TACE were repeated whenever the hepatic functional reserve of the patient permitted. We then analyzed the variables that could influence prognosis, including tumor size and number, the serum levels of AFP, the parameters of hepatic function (albumin, bilirubin, ALT, hepaplastin test, platelet number, and indocyanine green retention at 15 min (ICG-R15)), combined therapy with TACE, distant recurrence, and local recurrence.
Univariate analysis identified the ICG test, serum levels of AFP and albumin, tumor size and number, and local recurrence, but not distant recurrence, as significant prognostic variables. In multivariate analysis using those five parameters, the ICG test, tumor size, tumor number, and local recurrence were identified as significant prognostic factors. In both univariate and multivariate analyses, the relative risk for the ICG test was the highest, followed by local recurrence.
We found that local recurrence is an independent prognostic factor of HCC, indicating that achieving complete treatment for HCC on first treatment is important for improving the prognosis of patients with HCC.
阐明经皮乙醇注射治疗(PEIT)彻底治疗的重要性。
1988年至2002年共有140例未经治疗的肝癌患者纳入本研究。纳入标准为:直径小于4cm的孤立肿瘤或数量少于4个、直径小于3cm的多发肿瘤,无肝外转移或血管侵犯。作为肝癌治疗的一般原则,患者在接受PEIT之前先进行经动脉化疗栓塞术(TACE)。对患者进行初始治疗后,进行超声检查和计算机断层扫描,并测定血清甲胎蛋白(AFP)水平。当检测到肿瘤复发时,只要患者肝功能储备允许,就重复进行PEIT和/或TACE。然后我们分析了可能影响预后的变量,包括肿瘤大小和数量、AFP血清水平、肝功能参数(白蛋白、胆红素、谷丙转氨酶、肝促凝血酶原激酶试验、血小板数量以及15分钟吲哚菁绿潴留率(ICG-R15))、与TACE的联合治疗、远处复发和局部复发。
单因素分析确定吲哚菁绿试验、AFP和白蛋白血清水平、肿瘤大小和数量以及局部复发而非远处复发为显著的预后变量。在使用这五个参数的多因素分析中,吲哚菁绿试验、肿瘤大小、肿瘤数量和局部复发被确定为显著的预后因素。在单因素和多因素分析中,吲哚菁绿试验的相对风险最高,其次是局部复发。
我们发现局部复发是肝癌的一个独立预后因素,这表明首次治疗时对肝癌实现彻底治疗对改善肝癌患者的预后很重要。